Insmed vs Jazz Pharmaceuticals
INSM and JAZZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INSM and JAZZ compare
Insmed is the larger company, worth 1.8 times as much as Jazz Pharmaceuticals ($24.6B against $14.0B).
Insmed grew revenue faster over the last twelve months (240% versus 12.6% for Jazz Pharmaceuticals).
Jazz Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with −39.9% at Insmed.
Jazz Pharmaceuticals scores higher on the StockData Score (11 against 8 for Insmed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INSM | JAZZ |
|---|---|---|
| Size and price | ||
| Market cap | $24.6B | $14.0B |
| Share price | $112.58 | $215.98 |
| Change, 1 year | −32.6% | 59.1% |
| Change, 5 years | 237% | 59.9% |
| Beta (5Y) | 0.79 | 0.55 |
| Employees | 1,664 | 2,890 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 2 | 4 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 14.8× |
| P/S | 16.2× | 3.0× (better) |
| P/B | 33.9× | 2.9× (better) |
| EV/EBITDA | – | 18.0× |
| P/FCF | – | 8.8× |
| FCF yield | −2.6% | 11.4% (better) |
| Fair value | $61.67 | $254.92 |
| Margin of safety | −82.5% | 15.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 240% (better) | 12.6% |
| Revenue growth, 5Y average | 29.8% (better) | 12.5% |
| Profitability | ||
| Gross margin | 84.4% | – |
| Operating margin | −37.1% | 19.5% (better) |
| Net margin | −39.9% | 20.4% (better) |
| FCF margin | −41.3% | 34.6% (better) |
| Return on equity | −72.5% | 22.1% (better) |
| Return on invested capital | – | 12.1% |
| Financial health | ||
| Debt / equity | 0.76 (better) | 0.91 |
| Net debt / EBITDA | – | 2.40 |
| Interest coverage | −6.9× | – |
| Current ratio | 2.86 (better) | 1.78 |
| Altman Z-score | 6.56 (better) | 2.35 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 99.2% |
| Held by insiders | 0.88% | 3.4% |
| Insider net buying, 12 months | −$167M | −$68.0M (better) |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 6.4% | 8.7% |
Go deeper
- INSM stock overview
- INSM income statement
- INSM valuation and score
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
Other comparisons
- ALNY vs INSM
- ALNY vs JAZZ
- BBIO vs INSM
- INSM vs IONS
- INSM vs KNSA
- INSM vs MDGL
- INSM vs RPRX
- INSM vs UTHR
- JAZZ vs ONC
For information only, not investment advice. Check the source filings before relying on any figure.